1 NK cells and their functional characterization using degranulation, cytokine production, and proliferation assays. Results: We provide unequivocal evidence that PD-1 is highly expressed (PD-1
inhibitory coreceptor expressed on T cells. Notably, CTLA-4 has both cell-intrinsic (ie, on CTLA-4 1 effector cells) and extrinsic (on forkhead box P3-positive regulatory T cells) activities. As a consequence, deficiency in CTLA-4 function results in severe antigen-nonspecific autoimmune phenotypes. 10 In contrast, the effect of engaging PD-1 is mainly cell intrinsic. The cellintrinsic function of PD-1, as well as the regulation of PD-1 expression, might be responsible for the chronic and relatively milder pathologic phenotypes resulting from PD-1 blockade through either antibody-masking or genetic manipulation. Antibody-mediated blocking of PD-1 is now being exploited in clinics as a therapeutic tool for boosting immune responses in patients with different diseases, primarily in cancer. Importantly, targeting PD-1/PD-L1 interactions can also improve the efficacy of adoptive cell therapies in tumors or chronic viral infections. [11] [12] [13] [14] In some instances PD-1 blockade has been shown to mediate tumor eradication, [15] [16] [17] resulting in impressive and highly encouraging clinical results. Indeed, accumulating data indicate that the administration of an mAb to PD-1, used alone or in combination with other drugs, might provide a highly successful therapeutic tool in different types of advanced tumors, including melanoma, lung cancer, and ovarian carcinoma. [18] [19] [20] NK cell function is regulated by an array of germline-encoded surface receptors that, on interaction with their ligands, transmit either inhibitory or activating signals. [21] [22] [23] Mature human NK cells express inhibitory receptors specific for HLA class I molecules, including killer immunoglobulin-like receptors (KIRs), which are able to discriminate among different HLA-A, HLA-B, and HLA-C allotypes, 24 and the CD94/NKG2A heterodimer specific for HLA-E. 25, 26 These receptors allow NK cells to spare HLA class I 1 autologous normal cells and to kill cells in which HLA class I expression is downregulated (eg, by tumor transformation or viral infection) or allogeneic cells expressing nonself HLA class I alleles unable to engage inhibitory KIRs (an event that can occur in the haploidentical hematopoietic stem cell transplantation setting). 27, 28 Among the non-HLA-specific triggering receptors, NKp46, NKp30, NKp44 (collectively termed natural cytotoxicity receptors [NCRs]), 22 NKG2D, 29 DNAX accessory molecule-1 (DNAM-1; CD226), 26 and CD16 play a major role in NK cell activation. In addition, human NK subset is largely represented in PB (approximately 90%) and is characterized by high surface expression of KIRs, high cytotoxic activity against tumor-and virus-infected targets, and rapid production of cytokines on receptor-mediated cell activation. 34, 35 A constitutive or inducible expression of PD-1 has been detected in different cell populations, including T, B, and myeloid cells, 14, 36 whereas little is known regarding PD-1 expression on NK cells to date. In human subjects it has been reported that NK cells from patients with multiple myeloma 37 or patients with posttransplantation lymphoproliferative disorders 38 can express low PD-1 levels. On the other hand, expression of PD-1 by resting NK cells from immunocompetent healthy subjects has been poorly defined.
In the present study we show that PD-1 is expressed at high levels (PD-1 bright ) on a discrete subset of mature
CD57
1 NK cells in approximately one fourth of a large number of donors with no evident disease (thereafter defined as healthy donors [HDs] ) and, more frequently, in the PB of a cohort of patients with ovarian carcinoma. Functional analysis revealed that PD-1 1 NK cells display poor cytokineinduced proliferation and lower degranulation and cytokine production compared with PD-1 2 cells. Antibody-mediated disruption of the PD-1/PD-L interaction could revert, at least in part, the impaired NK cell degranulation against an ovarian carcinoma cell line. Remarkably, a relatively large PD-1 bright NK cell subset was detected in peritoneal fluid/ascites (PF) of patients with ovarian carcinoma, suggesting that PD-1 1 cells can be induced by the tumor microenvironment or recruited to the tumor site. Also, in this case the impaired NK cell degranulation was reversible with anti-PD-L antibodies.
METHODS

Patients and samples
This study included 200 buffy coats collected from volunteer blood donors admitted to the blood transfusion center of IRCCS S. Martino-IST after obtaining informed consent, and the study was approved by the Ethical Committee of IRCCS S. Martino-IST (39/2012). Thirty patients with seropapillary ovarian carcinoma subjected to primary surgery before chemotherapy (in accordance with a protocol approved by the Spedali Civili of Brescia institutional ethical board) were also enrolled, and informed consent was obtained from all patients according to the Declaration of Helsinki.
Isolation, culture of human leukocytes, and gate strategy Mononuclear cells were obtained from heparinized PB 39 and from PF of patients with ovarian carcinoma (after depletion of epithelial cell adhesion molecule [ESA] 1 and CD90 1 cells by using Magnetic Dynabeads Goat anti-Mouse IgG) 40 by means of density gradient centrifugation over Ficoll (Sigma, St Louis, Mo) and then resuspended in RPMI 1640 supplemented with 2 mmol/L glutamine, 50 mg/mL penicillin, 50 mg/mL streptomycin, and 10% heat-inactivated FCS (Societ a Prodotti Antibiotici, Milano, Italy).
Gate strategy
For more information on gate strategies, see Fig E1 in 
Statistical analysis
The independent samples t test was used for evaluating quantitative variables. The test is a statistical technique used to analyze the mean comparison of 2 independent groups. The statistical level of significance was preset at .05. Graphic representation and statistical analyses were performed with PASW Statistics, version 18.0, software (formerly SPSS Statistics; IBM, Segrate, Italy) and GraphPad Prism 6 (GraphPad Software, La Jolla, Calif).
RESULTS
PD-1 can be expressed by NK cells of HDs
Freshly isolated PB lymphocytes from a cohort of 200 HDs were assessed for the expression of PD-1 on NK cells by using cytofluorimetric analysis.
A subset characterized by a bright surface PD-1 expression was detected in about 25% of the donors analyzed (Fig 1, A and B) . PD-1 1 cells were confined to CD56 dim NK cells, whereas the CD56 bright subset was consistently PD-1 2 (Fig 1, B) . The percentage of PD-1 1 cells was variable among donors, ranging between 1.5% and 10%. In one donor displaying an expansion of the aberrant CD56
2
CD16
1 NK subset, 41, 42 PD-1 was found on both CD56 dim and CD56 2 NK cells, and the percentage of positive cells reached as much as 49% (Fig 1, B) .
Notably, analysis of the size of the PD-1 1 subset at different time points in various subjects revealed substantial stability over time. In Fig 1, C, 2 representative HDs are shown in whom the expression of PD-1 was unchanged for at least 1 year.
Because PD-1 1 NK cells were present only in some donors, it is possible that the expression of PD-1 might be related to infection. In this regard recent studies indicated that human cytomegalovirus (HCMV) infection leads to NK cell differentiation/ maturation and a reconfiguration in the NK cell receptor repertoire, including upregulation of the NKG2C activating receptor 43 and downregulation of the sialic acid-binding immunoglobulinlike lectin (Siglec) 7 (or p75/AIRM-1) inhibitory receptor.
42,44-46
Thus we analyzed PD-1 1 and PD-1 2 donors to figure out whether the expression of PD-1 correlated with altered expression of these NK cell markers.
We found that PD-1 1 subjects frequently display high proportions of NKG2C
1 cells, as well as a subset of Siglec-7 2 NK cells (Fig 2, A and B) . In addition, in most PD-1 1 donors the NKG2C 1 cell expansion was characterized by expression of an NKG2C bright (or NKG2C high ) phenotype (Fig 2, B) . 47, 48 These results suggested a possible association between PD-1 expression in NK cells and HCMV infection. 42, 45, 46, 49 Thus, when possible, HCMV seropositivity was also analyzed. We found that all the PD-1 1 subjects were seropositive for HCMV (Fig 2, C) .
Previous studies revealed that, among the surface molecules undergoing changes in expression after HCMV infection, an important group is represented by the HLA-specific receptors, including NKG2A, KIR, and leukocyte immunoglobulin-like receptor 1 (LIR-1). In particular, infection by HCMV favors expansion of KIR 1 and LIR-1 1 NK cells while reducing the fraction of NKG2A
1 NK cells. 42, 46 In addition, a subset of NKG2A
NK cells preferentially acquired CD57. 49 This molecule constitutes a marker of unknown function that is thought to identify mature/terminally differentiated NK cells. CD57
1 NK cells appear to be a stable subpopulation, increasing with age and exposure to pathogens (especially HCMV).
By comparing the PD-1 1 and PD-1 2 NK cell subsets derived from seropositive PD-1 1 HDs, we show that the PD-1 1 population is primarily composed of mature NKG2A
cells expressing CD57 (Fig 3, A) . In addition, different from PD-1 2 NK cells, only a minor fraction of PD-1 1 NK cells expressed Siglec-7 (Fig 3, A and B) , whereas NKG2C was expressed on both PD-1 1 and PD-1 2 NK cells (Fig 3, A and B) . Fig 3, B, shows expression of the above markers on PD-1 1 and PD-1 2 cells of a representative donor. Further analysis of additional cell-surface markers undergoing variation after HCMV infection in the PD-1 1 NK cell subset showed lower levels of NKp46, NKp30, CD160, and CD62 ligand expression (Fig 4, A) compared with the PD-1 2 subset. On the other hand, perforin/granzyme and CD16 were expressed at higher levels in PD-1 1 NK cells. Other receptors/markers, including 2B4 (CD244), IL-18 receptor a (IL-18Ra), NKG2D, and DNAM-1, were expressed at similar levels in PD-1 1 and PD-1 2 cells (Fig 4, A, and data not shown). The activation markers CD69, CD25, and NKp44 were substantially negative on both NK cell subsets (data not shown).
Finally, comparison between the PD-1 1 and PD-1 2 cell fractions of the (highly differentiated) NKG2A
1 cells display the lowest expression of NKp46 and NKp30 (Fig 4, B and C) . Altogether, these data indicate that expression of PD-1 is confined to NK cells with the phenotypic features of fully mature (terminally differentiated) NK cells. ). Because K562 cells do not express PD-L1/PD-L2, the differences detected could not reflect the interaction between PD-1 and its ligands but rather the low expression of the 2 main NCRs. Next, PD-1 1 and PD-1 2 NK cell subsets were assessed for degranulation in a reverse antibody-dependent cellular cytotoxicity (R-ADCC) assay against the murine FcgR 1 P815 mastocytoma cell line (PD-L1/PD-L2 negative). These experiments were performed in the absence or presence of mAbs specific for triggering NK receptors. The aim was to assess possible additional differences in degranulation after mAb-mediated cross-linking of activating receptors and coreceptors. As shown in Fig 5, B , both NK subsets undergo efficient degranulation in the presence of anti-CD16 or anti-NKp46 mAbs. However, in PD-1 1 cells the low surface expression of NKp46 resulted in less efficient responses to anti-NKp46 mAb. Interestingly, the 2 subsets displayed different abilities to respond to other triggering stimuli. Thus the combined use of mAbs specific for DNAM-1 and 2B4 coreceptors induced degranulation of PD-1 2 but not PD-1 1 NK cells (Fig 5, B) .
Another series of R-ADCC experiments was performed by using anti-PD-1 mAb in combination with anti-NKp46 or anti-CD16 mAbs. The aim of these experiments was to assess whether mAb-mediated cross-linking of PD-1 could inhibit NK cell activation induced by cross-linking of the triggering receptors. As shown in Fig 5, C and F , mAb-mediated cross-linking of PD-1 resulted in a partial but significant reduction of NK cell responses to triggering receptors.
We further analyzed the effect of engagement of PD-1 by its ligands (PD-L1/PD-L2) expressed on the tumor cell line OVCAR5 (ovarian carcinoma). 54 In these experiments the expression of CD107a on NK cells was analyzed after shortterm exposure of NK cells to OVCAR5 in the presence or absence of anti-PD-L1/PD-L2 mAbs, which are capable of blocking the interaction between PD-1 and its ligands (mAb-mediated masking experiments). As shown in Fig 5, D and G, PD-1 2 NK cells displayed a substantial mobilization of CD107a, both in the absence and presence of anti-PD-L1/PD-L2 mAbs. In contrast, degranulation of PD-1 1 NK cells was reduced and could be restored, at least in part, by anti-PD-L1/PD-L2 mAbs. Note that we performed experiments also in the presence of anti-HLA class I mAbs (A6/136) 55 to disrupt the inhibitory interaction between KIRs and HLA class I molecules (expressed at high levels on the surface of OVCAR5 ; Fig 5, D and G) . Altogether, these experiments indicate that PD-1 1 NK cells display a low cytolytic activity against tumor targets, even when these cells lack PD-L1/PD-L2 expression (ie, K562). In addition, the inhibition of NK cell degranulation induced by cross-linking PD-1 and its ligands on OVCAR5 tumor cells was reverted only in part by mAbs specific for PD-L1/PD-L2. A and C, IFN-g production after stimulation with K562 (6 donors and 1 representative donor, respectively). E and G, TNF-a production after stimulation with K562 (6 donors and 1 representative donor, respectively). B and D, IFN-g production on stimulation with P815 in the presence or absence of the indicated mAbs (6 donors and 1 representative donor, respectively). F and H, TNF-a production on stimulation with P815 in the presence or absence of the indicated mAbs (6 donors and 1 representative donor, respectively). *P < .05 and **P < .01. Gate strategy used: C. Interestingly, the impaired killing/degranulation of PD-1
1
(compared with PD-1 2 ) cells could be overcome by strong stimuli, such as cell triggering through CD16 (in R-ADCC). In this case it is likely that the low level of NCR expression by PD-1 1 NK cells might be counterbalanced (at least in part) by the expression of high levels of CD16 and perforin/granzyme (Fig 4, A) .
Cells were stimulated with K562 or P815 tumor target cells and assessed for production of IFN-g and TNF-a in a flow cytometric assay using intracellular staining to determine whether PD-1 1 NK cells would also display an altered capability of releasing cytokines. As shown in Fig 6, K562 -induced NK cell activation resulted in production of IFN-g (Fig 6, A and C) and TNF-a (Fig 6, E and G) by most PD-1 2 but only a small fraction of PD-1 1 NK cells. Remarkably, similar to degranulation, IFN-g and TNF-a production could be induced in PD-1 1 NK cells by anti-CD16 mAbs in a redirected-antibody dependent stimulation assay (P815 cells plus mAb). On the other hand, when anti-CD16 was combined with anti-PD-1 mAb, a significantly lower fraction of PD-1 1 NK cells produced cytokines compared with PD-1 2 NK cells (Fig 6, B, D, F, and H) .
Next, the PD-1 1 and PD-1 2 subsets were analyzed for their capacity to proliferate (by using the carboxyfluorescein succinimidyl ester [CFSE] dilution assay measured at 5 days of culture) in response to rhIL-2 or rhIL-15. As shown in Fig 7, A, PD-1 1 NK cells are poorly responsive to low doses of rhIL-2 or rhIL-15, whereas they undergo proliferation at higher cytokine doses, although at lower rates than PD-1 2 NK cells. A similar difference in the capacity to respond to cytokines was observed also between the PD-1 1 and PD-1 2 cell fractions of the NKG2A 2 KIR 1 CD57
1 NK cell population (Fig 7, B) . Thus proliferation of PD-1 1 NK cells is impaired in the presence of low cytokine concentrations, a condition that can occur in certain tumor microenvironments. 
Expression and function of PD-1 on NK cells from patients with tumors
In these experiments we analyzed whether PD-1 1 NK cells could be found also in PB and PF of patients affected by seropapillary ovarian carcinoma. 40 PD-1 1 cells could be detected in the PB of the majority of these patients. In addition, in given patients they were present in higher proportions in PF than in PB of the same patients (Fig 8, A and C) . Although, as previously reported, 40 the size of the CD56 bright NK cell subsets was usually larger in PF NK cells compared with PB NK cells of the same patients, PD-1 1 NK cells were confined to the CD56 dim NK cell subset (Fig 8, B) . Notably, the size of the PD-1 1 NK cell subsets detected in PB of the patients was slightly larger than in PBs of HDs (Fig 8, C) .
Altogether, these data indicate that PD-1 1 NK cells might be significantly enriched at the tumor site. As shown in Fig 8, D and E (and not shown), and in agreement with data obtained in HDs, the ability of PD-1 1 PF NK cells to degranulate was lower than that of PD-1 2 PF NK cells. Note that the use of mAbs suitable for disrupting the interaction between PD-1 and its ligands might restore the altered functional capability of PD-1
1
NK cells toward PD-L1/PD-L2
1 tumor target cells (OVCAR5, ovarian carcinoma) (Fig 8, D and E) . This suggest that in patients with ovarian carcinoma, the impaired functional capability of PD-1 1 NK cells can be rescued in vivo by mAbs targeting the PD-1/PD-L axis of the NK/tumor crosstalk.
DISCUSSION
In the present study we show that PD-1 is brightly expressed by a subset of PB NK cells in a fraction of otherwise healthy subjects. ) NK cells, which are characterized by low NCR and high CD16, perforin, and granzyme expression. As to their functional capabilities, PD-1 1 NK cells show impaired proliferative responses to exogenous rhIL-2 and rhIL-15. In addition, degranulation/cytotoxic activity and cytokine production in response to tumor cells are significantly lower in PD-1 1 than PD-1 2 NK cells. The expression and function of PD-1 have been analyzed mainly in normal peripheral T cells and tumor-infiltrating lymphocytes, [56] [57] [58] whereas only a few studies have been focused on NK cells. In these studies the expression of PD-1 was detected in PB NK cells derived from patients 37, 38, 59, 60 but not from HDs. In addition, the level of expression reported was very low, thus rendering it difficult to discriminate between PD-1 1 and PD-1 2 cells and to identify a distinct subset of PD-1 1 cells. Because of these limitations, no attempts have been made to characterize the PD-1 1 NK cell subset for phenotypic and functional properties.
Here we show that some HDs express sizeable levels of PD-1 on CD56
dim NK cells and that the size of the PD-1 1 NK cell subset varied among donors. Notably, analysis of the size of the PD-1 1 subset in given subjects at different time points revealed a substantial stability (Fig 1, C) . The fact that a PD-1 1 NK cell subset could be detected in only some of the subjects analyzed might be a result of latent chronic infections affecting these subjects (in this context it is of note that an increase in PD-1 1 lymphocyte numbers has been associated with hepatitis C virus, hepatitis B virus, and HIV infections). 6, 7, [61] [62] [63] Although a correlation exists between the presence of PD-1 1 NK cells and HCMV infection, phenotypic analysis of PD-1 1 NK cells showed that NKG2C (the expression of which is associated to HCMV infection) is not preferentially expressed by PD-1 1 cells. However, similar to NKG2C
1 NK cells accumulating in response to HCMV infection, the PD-1 1 subset was almost exclusively composed of highly differentiated NKG2A 2 KIR 1 CD57 1 NK cells. In line with this phenotypic feature, PD-1 1 cells expressed very low levels of NCRs (the lowest among CD57
1 NK cells) but high levels of CD16. Conceivably, the impaired degranulation and cytokine production in response to tumor target cells (K562) is consequent to the defective expression of NCRs. In this context it is of note that B7-H6, a major surface ligand of NKp30, is expressed by K562 cells. 53 On the other hand, in line with their high content of perforin/granzyme and their high expression of CD16, PD-1 1 NK cells could degranulate to levels comparable with PD-1 2 cells in response to anti-CD16 mAbs in R-ADCC. [50] [51] [52] Thus under this experimental condition, the impaired degranulation of PD-1 1 NK cells caused by downregulation of NCRs (NKp30 and NKp46) can be bypassed by a potent stimulus delivered by CD16. Based on the recovery of different functions (cytokine release and cytotoxicity) on cell triggering through CD16 in R-ADCC, it is unlikely that PD-1 1 NK cells merely represent a population of exhausted cells with an intrinsic functional defect. Indeed, their functional impairment appears to be mainly consequent to a profound imbalance between inhibitory and triggering signals, reflecting the upregulation/downregulation of different receptors. Notably, in line with this concept, the reduced degranulation of PD-1 1 cells after interaction with OVCAR5 reflects not only the poor NCR-mediated cell activation but also the inhibitory J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 1 signal mediated by PD-1 on interaction with PD-L1/PD-L2 expressed on these target cells. In this case disruption of the PD-1/PD-L interaction mediated by anti-PD-L mAbs could partially revert functional inhibition. Thus cross-linking of PD-1 mediated by either anti-PD-1 mAbs in R-ADCC (Fig 5, C and F) or by the engagement of PD-L expressed on target cells (Fig 5, D and G) can lead to impaired PD-1 1 NK cell function.
The sharply reduced proliferative responses of PD-1 1 NK cells to low concentrations of exogenous rhIL-2 and rhIL-15 is in line with the finding in mice that highly differentiated memory NK cells display reduced responses to soluble microenvironmental cytokines. 64 Thus it is conceivable that also human CD57 1 NK cells can be poorly responsive because they express low amounts of CD122 (IL-2 receptor b, a subunit of the shared receptor for IL-2 and IL-15). [50] [51] [52] 65 In addition, the PD-1 1 NK cell subset is characterized by the lowest CD122 expression among CD57 1 NK cells (data not shown). Moreover, IFN-g production by PD-1 1 NK cells in response to exogenous rhIL-12 plus rhIL-18 was highly defective (data not shown). [50] [51] [52] Thus it is conceivable that PD-1 1 NK cells might represent a population of poorly proliferating cells that could be induced to divide only by high concentrations of microenvironmental cytokines, as suggested by our present data.
PD-1 1 NK cells were detected more frequently in the PB of a cohort of patients with seropapillary ovarian carcinoma than in HDs. More importantly, PD-1 1 cells could be recovered from the PF of most of these patients. 40 Remarkably, the size of such PF PD-1 1 subsets was much larger than in PB from the same subjects. In some patients PD-1 1 NK cells were present in PF but not in PB. It is possible that in these cases the size of the PB PD-1 1 subset could be less than the limit of detectability. Altogether, these data suggest that PD-1 1 NK cells are present more frequently in the PB of patients with certain tumors. In addition, this PD-1 1 subset might be greatly increased in size in tumor-associated NK cells, as in the case of PF. Functionally, PD-1 1 NK cells isolated from PF display frequently a markedly compromised capability of degranulating on interaction with PD-L1/PD-L2 1 tumor target cells. Remarkably, mAb-mediated disruption of PD-1/PD-L interaction could partially restore the NK cell function.
Because PD-1 1 cells have been detected in some HDs, it is possible that latent chronic diseases (eg, viral infections) might be responsible for PD-1 induction in NK cells. Indeed, a correlation has been established between HCMV seropositivity and the presence of PB PD-1 1 NK cells (Fig 2, C) . One might speculate that both virus-driven signals and the tumor microenvironment can contribute to PD-1 expression on NK cells in the case of patients with ovarian carcinoma.
It is evident that the study of other tumors and infectious diseases is needed to further confirm a correlation with the presence/induction of PD-1 1 cells. Remarkably, in a recent study, the clinical efficacy of an anti-PD-1 mAb has been reported in patients with ovarian carcinoma. 66 It is possible that the beneficial effects documented in this study might reflect not only a blockade of PD-1/PD-L on tumor-infiltrating lymphocytes but also on PD-1 1 NK cells. In conclusion, because NK cells are potent effectors with strong cytolytic activity against tumor cells, the finding that PD-1 can be expressed on these cells, particularly in patients with cancer, suggests a possible involvement of the PD-1-mediated inhibitory pathway in the impaired NK cell responses against tumors. Our present finding further supports the notion that PD-1 signaling might downregulate not only cytotoxic T lymphocytemediated adaptive responses but also innate responses. Therefore it is conceivable that therapies targeting the PD-1/PD-L axis might rescue not only cytotoxic T-lymphocyte activity but also NK-mediated function. In this context it should be stressed that although in conventional NK cells the effector function is primarily regulated by HLA class I-specific inhibitory receptors (KIR family and CD94/NKG2A)/HLA class I molecule interactions, in the case of PD-1 1 NK cells, an additional potent inhibitory pathway might contribute to limit NK cell function. In this case downregulation of HLA class I molecules on tumor cells can be offset by the expression of PD-1 ligands. It is possible that the simultaneous expression of PD-1 together with given inhibitory HLA-specific receptors might provide an additional level of suppression of NK cell antitumor responses and that (mAb-mediated) blocking of different inhibitory checkpoints, including PD-1, might be required to obtain optimal NK cell responses.
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Key messages
d Unequivocal evidence that PD-1 is highly expressed by a subset of NK cells detectable in a fraction of healthy subjects.
1 , a phenotypic feature typical of terminally differentiated NK cells. On interactions with tumor cells, they display impaired degranulation/cytotoxic activity and cytokine production and elicit poor proliferation in response to exogenous cytokines. The impaired degranulation against an ovarian carcinoma cell line can be reversed by anti-PD-L antibodies. Note: In the APC-Cy7/APC-H7 channel, the fluorochrome used is always APC-Cy7, except in the CD107a degranulation experiments. Further details on mAbs are included in the section "Monoclonal antibodies (mAbs)" in the Online Repository Material and Methods.
FIG E2.
Staining panels of mAbs used in the various experiments (functional and cell-surface/intra phenotypic analysis).
